Vijay Ramakrishnan, PhD

  • 357 Citations
  • 9 Scopus h-Index
20102019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 357 Citations
  • 9 Scopus h-Index
  • 13 Article
  • 2 Review article
2019

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

Ramakrishnan, V. G., Miller, K. C., Macon, E. P., Kimlinger, T. K., Haug, J., Kumar, S., Gonsalves, W. I., Vincent Rajkumar, S. & Kumar, S. K., 2019, In : Haematologica. 104, 10, p. 2061-2074 14 p.

Research output: Contribution to journalArticle

Open Access
4 Scopus citations
2018

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma

Painuly, U., Ramakrishnan, V., Kimlinger, T., Wellik, L., Haug, J., Gonsalves, W., Bi, L., Huang, Z., Rajkumar, S. V. & Kumar, S., Oct 1 2018, In : Oncotarget. 9, 77, p. 34582-34594 13 p.

Research output: Contribution to journalArticle

2 Scopus citations

Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies

Gonsalves, W. I., Ramakrishnan, V., Hitosugi, T., Ghosh, T., Jevremovic, D., Dutta, T., Sakrikar, D., Petterson, X. M., Wellik, L., Kumar, S. K. & Nair, K. S., Jan 11 2018, In : JCI Insight. 3, 1

Research output: Contribution to journalArticle

Open Access
6 Scopus citations

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

Ramakrishnan, V. & Kumar, S. K., Jan 12 2018, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

Research output: Contribution to journalArticle

10 Scopus citations
2016
1 Scopus citations

Signaling Pathways and Emerging Therapies in Multiple Myeloma

Ramakrishnan, V. & D’Souza, A., Apr 1 2016, In : Current Hematologic Malignancy Reports. 11, 2, p. 156-164 9 p.

Research output: Contribution to journalReview article

8 Scopus citations

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma

Ramakrishnan, V., Gomez, M., Prasad, V., Kimlinger, T., Painuly, U., Mukhopadhyay, B., Haug, J., Bi, L., Vincent Rajkumar, S. & Kumar, S., 2016, In : Oncotarget. 7, 35, p. 56253-56265 13 p.

Research output: Contribution to journalArticle

9 Scopus citations
2014

Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma

Ramakrishnan, V., Painuly, U., Kimlinger, T., Haug, J., Rajkumar, S. V. & Kumar, S., Jul 2014, In : Leukemia. 28, 7, p. 1519-1528 10 p.

Research output: Contribution to journalArticle

27 Scopus citations

Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001

Ramakrishnan, V., Kimlinger, T., Timm, M., Haug, J., Rajkumar, S. V. & Kumar, S., Nov 1 2014, In : Leukemia Research. 38, 11, p. 1358-1366 9 p.

Research output: Contribution to journalArticle

8 Scopus citations
2012

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

Ramakrishnan, V., Kimlinger, T., Haug, J., Painuly, U., Wellik, L., Halling, T., Rajkumar, S. V. & Kumar, S., Nov 21 2012, In : PloS one. 7, 11, e50005.

Research output: Contribution to journalArticle

40 Scopus citations

Bortezomib Combination Therapy in Multiple Myeloma

Kapoor, P., Ramakrishnan, V. & Rajkumar, S. V., Jul 1 2012, In : Seminars in Hematology. 49, 3, p. 228-242 15 p.

Research output: Contribution to journalArticle

50 Scopus citations

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

Ramakrishnan, V., Ansell, S., Haug, J., Grote, D., Kimlinger, T., Stenson, M., Timm, M., Wellik, L., Halling, T., Rajkumar, S. V. & Kumar, S., Feb 1 2012, In : Leukemia. 26, 2, p. 340-348 9 p.

Research output: Contribution to journalArticle

45 Scopus citations

Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

Ramakrishnan, V., Timm, M., Haug, J. L., Kimlinger, T. K., Halling, T., Wellik, L. E., Witzig, T. E., Vincent Rajkumar, S., Adjei, A. A. & Kumar, S., Mar 1 2012, In : American journal of hematology. 87, 3, p. 277-283 7 p.

Research output: Contribution to journalArticle

23 Scopus citations
2010

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Ramakrishnan, V., Timm, M., Haug, J. L., Kimlinger, T. K., Wellik, L. E., Witzig, T. E., Rajkumar, S. V., Adjei, A. A. & Kumar, S., Feb 1 2010, In : Oncogene. 29, 8, p. 1190-1202 13 p.

Research output: Contribution to journalArticle

77 Scopus citations
47 Scopus citations